SpectrumX Reaches Partnership Agreement on Human Volunteer Study for Ground-breaking Respiratory Infection Drug Candidate SPX-001

Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001 Partner and SpectrumX will align on detailed clinical trial protocol to discuss with the MHRA at Scientific Advisory Meeting, currently scheduled for 14 November 2022 LONDON–(BUSINESS WIRE)–SpectrumX, a UK-based healthcare and pharmaceutical company, … [Read more…]

The Fifth CIIE Is Ready to Open Its Door to Worldwide Participants

SHANGHAI–(BUSINESS WIRE)–$CHINA #china–Acting as a major platform for international procurement, investment promotion, cultural exchanges and open cooperation, the China International Import Expo (CIIE) has been held for four consecutive years and is widely regarded as an international public good, which in turn is good for economic globalization and multilateral trading system. With a number of … [Read more…]

SHOP APOTHEKE EUROPE: New Italian Distribution Centre Fully Operational.

SEVENUM, Netherlands–(BUSINESS WIRE)–SHOP APOTHEKE EUROPE looks back on the successful opening of its new distribution centre in Milan, Italy. After the first package had left the site on July 4, the official inauguration ceremony took place last Friday along with the management and the Italian employees on site. As officially announced earlier this year, 100% … [Read more…]

NETRIS Pharma, Orano and Centre Léon Bérard Announce Scientific Collaboration to Develop Novel Antibody Radio-Conjugate Therapies

Aims to combine NETRIS Pharma’s mAb with selected radioisotopes LYON, France–(BUSINESS WIRE)–NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with Orano and the Centre Léon Bérard (CLB) to develop novel Antibody Radio-Conjugates for the treatment of cancer. Initially, the parties intend to conduct a … [Read more…]

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good … [Read more…]

Customers consider insurers as preferred providers for physical and financial wellness advice

Over two thirds of customers are interested in physical and financial wellness, yet only 8% of insurers have established the necessary capabilities. PARIS–(BUSINESS WIRE)–Capgemini and Qorus’ inaugural World Life and Health Insurance Report, published today, reveals that customers consider insurers among the top two preferred providers1 for physical and financial wellness advice. However, most insurers … [Read more…]

Otsuka Medical Devices Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting

Study of the Paradise™ Ultrasound Renal Denervation System Shows significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension TOKYO–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) a wholly owned subsidiary of Otsuka Holdings today announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating the endovascular Paradise™ Ultrasound Renal … [Read more…]

Virios Therapeutics, Inc. Announces Pricing of Public Offering

ATLANTA–(BUSINESS WIRE)–$VIRI #Biotech–Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of … [Read more…]

AHF Pledges $10 Million to the Global Fund

NEW YORK–(BUSINESS WIRE)–Ahead of the Seventh Replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria in New York City on Sept. 21, AIDS Healthcare Foundation (AHF) announced that it will pledge $10 million to the Fund – the world’s best financing mechanism for fighting infectious diseases. “Given the Global Fund’s outstanding track record … [Read more…]

NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment

BRUKINSA Is the First Bruton’s Tyrosine Kinase (BTK) Inhibitor Recommended by NICE for Routine Use for WM BRUKINSA Is the Only BTK Inhibitor Considered Cost Effective in WM CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced … [Read more…]